Kostenuik PJ - Search Results

1

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.

Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC. Canon JR, et al. Among authors: kostenuik pj. Clin Exp Metastasis. 2008;25(2):119-29. doi: 10.1007/s10585-007-9127-1. Epub 2007 Dec 5. Clin Exp Metastasis. 2008. PMID: 18064531

2

A quantitative model for spontaneous bone metastasis: evidence for a mitogenic effect of bone on Walker 256 cancer cells.

Kostenuik PJ, Singh G, Suyama KL, Orr FW. Kostenuik PJ, et al. Clin Exp Metastasis. 1992 Nov;10(6):403-10. doi: 10.1007/BF00133469. Clin Exp Metastasis. 1992. PMID: 1451350

3

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.

Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ. Li J, et al. Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1566-71. doi: 10.1073/pnas.97.4.1566. Proc Natl Acad Sci U S A. 2000. PMID: 10677500 Free PMC article.

4

Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.

Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan CR. Capparelli C, et al. Among authors: kostenuik pj. Cancer Res. 2000 Feb 15;60(4):783-7. Cancer Res. 2000. PMID: 10706080

5

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis.

Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Min H, et al. Among authors: kostenuik pj. J Exp Med. 2000 Aug 21;192(4):463-74. doi: 10.1084/jem.192.4.463. J Exp Med. 2000. PMID: 10952716 Free PMC article.

6

Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis.

Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, Mao M, Kostenuik P, Dunstan CR, Lacey DL, Sheng JZ. Bolon B, et al. Mol Ther. 2001 Feb;3(2):197-205. doi: 10.1006/mthe.2001.0245. Mol Ther. 2001. PMID: 11237676 Free article.

7

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.

Kostenuik PJ, Shalhoub V. Kostenuik PJ, et al. Curr Pharm Des. 2001 May;7(8):613-35. doi: 10.2174/1381612013397807. Curr Pharm Des. 2001. PMID: 11375772 Review.

8

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.

Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Morony S, et al. Among authors: kostenuik pj. Cancer Res. 2001 Jun 1;61(11):4432-6. Cancer Res. 2001. PMID: 11389072

9

OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats.

Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR. Kostenuik PJ, et al. Endocrinology. 2001 Oct;142(10):4295-304. doi: 10.1210/endo.142.10.8437. Endocrinology. 2001. PMID: 11564687

10

Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis.

Bolon B, Shalhoub V, Kostenuik PJ, Campagnuolo G, Morony S, Boyle WJ, Zack D, Feige U. Bolon B, et al. Among authors: kostenuik pj. Arthritis Rheum. 2002 Dec;46(12):3121-35. doi: 10.1002/art.10680. Arthritis Rheum. 2002. PMID: 12483715 Free article. Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters